Literature DB >> 21151211

Hyponatremia: vasopressin antagonists in hyponatremia: more data needed.

Richard Sterns, John Hix.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21151211     DOI： 10.1038/nrneph.2010.173

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

Review 1.  Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis.

Authors:  Benaya Rozen-Zvi; Dafna Yahav; Mihai Gheorghiade; Asher Korzets; Leonard Leibovici; Uzi Gafter
Journal:  Am J Kidney Dis       Date:  2010-06-09       Impact factor: 8.860

2.  Treating profound hyponatremia: a strategy for controlled correction.

Authors:  Richard H Sterns; John Kevin Hix; Stephen Silver
Journal:  Am J Kidney Dis       Date:  2010-08-14       Impact factor: 8.860

3.  Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.

Authors:  Benoit Renneboog; Wim Musch; Xavier Vandemergel; Mario U Manto; Guy Decaux
Journal:  Am J Med       Date:  2006-01       Impact factor: 4.965

4.  Oral tolvaptan is safe and effective in chronic hyponatremia.

Authors:  Tomas Berl; Friederike Quittnat-Pelletier; Joseph G Verbalis; Robert W Schrier; Daniel G Bichet; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 10.121

5.  Mortality after hospitalization with mild, moderate, and severe hyponatremia.

Authors:  Sushrut S Waikar; David B Mount; Gary C Curhan
Journal:  Am J Med       Date:  2009-09       Impact factor: 4.965

6.  DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia.

Authors:  Anjana Perianayagam; Richard H Sterns; Stephen M Silver; Marvin Grieff; Robert Mayo; John Hix; Ruth Kouides
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

7.  Hypertonic saline for hyponatremia: risk of inadvertent overcorrection.

Authors:  Hashim K Mohmand; Dany Issa; Zubair Ahmad; Joseph D Cappuccio; Ruth W Kouides; Richard H Sterns
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-03       Impact factor: 8.237

8.  Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.

Authors:  Juan Carlos Q Velez; Shirley J Dopson; Donna S Sanders; Tracie A Delay; John M Arthur
Journal:  Nephrol Dial Transplant       Date:  2010-01-11       Impact factor: 5.992

Review 9.  The treatment of hyponatremia.

Authors:  Richard H Sterns; Sagar U Nigwekar; John Kevin Hix
Journal:  Semin Nephrol       Date:  2009-05       Impact factor: 5.299

10.  Hyponatremia-induced osteoporosis.

Authors:  Joseph G Verbalis; Julianna Barsony; Yoshihisa Sugimura; Ying Tian; Douglas J Adams; Elizabeth A Carter; Helaine E Resnick
Journal:  J Bone Miner Res       Date:  2010-03       Impact factor: 6.741
  10 in total
  3 in total

Review 1.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

2.  Treatment of Hyponatremia with Tolvaptan in a Patient after Neurosurgical Treatment of a Pituitary Tumor: Case Report and Review of Literature.

Authors:  Shinya Ichimura; Rudolf Fahlbusch; Wolf Lüdemann
Journal:  J Neurol Surg Rep       Date:  2015-10-25

3.  The utility and accuracy of four equations in predicting sodium levels in dysnatremic patients.

Authors:  Ramy Magdy Hanna; Wan-Ting Yang; Eduardo A Lopez; Joseph Nabil Riad; James Wilson
Journal:  Clin Kidney J       Date:  2016-05-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.